-
Science: Novel gene therapies targeting overactive brain cells hold promise for treating neurological disorders
Time of Update: 2023-01-05
To develop the new gene therapy, the authors screened several genes known to be activated in response to stimuli and coupled their promoters to potassium channels selected for reducing nerve cell firing.
com)Resources:Yichen Qiu et al.
-
China Cell Holding Subsidiary Submits Adalimumab Biosimilar Drug Listing Application
Time of Update: 2022-01-11
On December 16, China Cell Engineering, a holding subsidiary of China Cell Biology Group, submitted an application for the listing of Adalimumab (SCT630) biosimilar drug . SCT630 is a recombinant ful
-
Shenzhou Cell: Recombinant New Coronavirus Vaccine Product of Holding Subsidiary Received Drug Clinical Trial Approval
Time of Update: 2022-01-01
SCTV01C is a recombinant new coronavirus Alpha+Beta mutant strain independently developed by Shenzhou Cell Engineering to address the problems of the first-generation domestic and foreign vaccines based on the original strain of the new coronavirus, such as the reduction of the neutralizing antibody titer and the protection rate of the mutant strain.
-
Shenzhou Cell Holding Subsidiary New Crown Neutralizing Antibody Drug Approved for Clinical Clinic
Time of Update: 2022-01-01
SCTA01 is a recombinant anti-SARS-CoV-2 spike protein monoclonal antibody independently developed by Shenzhou Cell Engineering.
SCTA01C is a new coronavirus monoclonal neutralizing antibody independently developed by Shenzhou Cell Engineering.
-
Only one year after its establishment, it has cooperated with Gilead and Baekje, holding more than
Time of Update: 2021-11-14
FT516 clinical data (source: Fate official website) Frank Yu, the founder/CEO of Huiqiao Capital, who led this round of Shoreline financing, said that they have been investigating the field of iPSC-derived NK cell therapy for many years, and that this field has made encouraging clinical progress.
-
Cell︱ hold hands, advance and retreat together!
Time of Update: 2021-10-22
These results indicate that the transfer of α-syn fibrils between cells can down-regulate the expression of inflammation-related genes in microglia (Figure 4) .
-
Tecentriq first-line treatment of metastatic non-small cell lung cancer, CHMP holds positive opinions
Time of Update: 2021-04-13
Roche announced today that the European Medicines Management Agency (EMA) Committee for Medicinal human use (CHMP) has recommended approval of the Tecentriq® (atezolizumab) as a high expression of PD-L1 and no epidermal growth factor receptor (EGFR) or anaplastic lymphoma First-line therapy for metastatic non-small cell lung cancer ( NSCLC ) with abnormal genomic tumors of ALK .
-
Opdivo (nivolumab) combined with Cabometyx (cabozantinib) in the first-line treatment of advanced renal cell carcinoma, CHMP holds positive opinions
Time of Update: 2021-03-20
The results showed that, compared with sunitinib , the progression-free survival (PFS), overall survival (OS) and objective response rate (ORR) of patients in the Opdivo (nivolumab) combined with Cabometyx (cabozantinib) group were significantly improved.
-
Development Cell: Breast cancer cells use exocystic "dialogue" to hold normal cells hostage.
Time of Update: 2020-09-03
in their study, Altieri's team cultured breast cancer cells in a low-oxygen environment to simulate hypoxia, a hallmark of the micro-environment around most solid tumors, and studied the extracellular follicles (EVs) released by these cells.
-
"Future of pulse cell therapy" Guangzhou will hold the annual international biotechnology conference in August
Time of Update: 2019-05-31
[pharmaceutical Station exhibition report] for thousands of years, human beings have adopted biotechnology in agriculture, food, medicine and other fields The early biotechnology can even be traced ba
